JUN 03, 2020 8:00 AM PDT

Keynote Presentation: It is Time for TIME (Tumor Immune Microenvironment) in Experimental and Diagnostic Pathology

Sponsored by: Leica Biosystems
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Cancer initiation and virulence depends on mechanisms to evade host immunosurveillance and suppression of early invasion and growth.  Distinct phenotypes of the immune infiltrates in and around cancers derive from differing mechanisms.  Some very good prognosis cancers are immune "deserts" with very little immune cell infiltration.  These tumors register as normal or self to the immune system, accompanied by a more normal (less aggressive) behavior.  Meanwhile, the most aggressive appearing cancers elicit the most inflammation.  These tumors employ a variety of mechanisms to evade immune suppression.  The now well known immune checkpoint PDL1 aberrantly expressed by tumor cells (or induced in surrounding immune cells) has provided a critical target for therapy, effecting cures in a subset of previously incurable patients.  Overall, however, this remains a small subset. Advanced generation mouse models provide an opportunity to explore new treatment protocols.  For example, we have shown that immune "priming" augments PDL1 checkpoint inhibitor therapy.  In another model, we find that tumors with an "immune excluded" phenotype, where a brisk infiltrate is seen surrounding but not infiltrating a tumor, can be attributed to the simultaneous expression of macrophage chemoattracting and repelling paracrine factors.  HER2 amplification, seen in 15% of invasive breast cancers but twice as many intraductal cancers (DCIS) provides a prototype tumor antigen and another opportunity to explore rational combinations of immune and cell targeted therapies.  There is growing list of additional immune synapse targets with drugs in development and clinical trials now.  Meanwhile, predictive biomarkers for specific targets or combinations of targets are also in active development.  As we and others have shown, advanced generation mouse models of human disease play a critical role in the development of mechanistic evidence for new therapies and new diagnostic and predictive biomarkers.

Learning Objectives:

1. Review patterns and mechanisms of the tumor immune microenvironment

2. Understand examples of experimental pathology in immune intact models of disease

3. Promote active interest in the evolving field of cancer immunotherpy as a personalized medicine approach


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
APR 01, 2021 8:00 AM PDT
C.E. CREDITS
APR 01, 2021 8:00 AM PDT
Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
Loading Comments...
Show Resources